Resveratrol in the management of human cancer: How strong is the clinical evidence?

Annals of the New York Academy of Sciences

Volumn 1290, Issue 1, 2013, Pages 12-20

  Gescher, Andreas ^a   Steward, William P ^a   Brown, Karen ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Biomarkers; Cancer; Clinical trial; Colon; Pharmacokinetics; Resveratrol

Indexed keywords

BORTEZOMIB; MIDAZOLAM; PLACEBO; RESVERATROL;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CHEMOPROPHYLAXIS; CHILL; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FLUSHING; GASTROINTESTINAL TOXICITY; HUMAN; LIVER METASTASIS; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; SIDE EFFECT; SKIN IRRITATION; URINARY EXCRETION;

EID: 84880344982     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12205     Document Type: Article

References (39)

1. Baur, J.A. & D.A. Sinclair. 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discover. 5: 493-506.
2. Smoliga, J.M., J.A. Baur & H.A. Hausenblas. 2011. Resveratrol and health-a comprehensive review of clinical trials. Mol. Nutr. Food Res. 55: 1129-1141.
3. Patel, K.R., E. Scott, V.A. Brown, et al. 2011. Clinical trials of resveratrol. Ann. N.Y. Acad. Sci. 1215: 161-169.
4. Patel, K.R., W.P. Steward, A.J. Gescher & K. Brown. 2012. Clinical development of resveratrol. In Resveratrol: Sources, Production and Health Benefits. Chapter 23, Delmas, D., Ed.: 511-532. Nova Science Publishers, Huntington, NY.
5. Jang, M., L. Cai, G.O. Udeani, et al. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
6. Bishayee, A. 2009. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. 2: 409-418.
7. Pezzuto, J.M. 2008. Resveratrol as an inhibitor of carcinogenesis. Pharmaceutical Biol. 46, 443-457.
8. Baur, J.A., K.J. Pearson, N.L. Price, et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.
9. Price, N.L., A.P. Gomes, A.J.Y. Ling, et al. 2012. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 15: 675-690.
10. Vang, O., N. Ahmad, C.A. Baile, et al. 2011. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 6, e19881.
11. Scott, E.N., A.J. Gescher, W.P. Steward & K. Brown. 2009. Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. Cancer Prev. Res. 2: 525-530.
12. Kelloff, G.J., S.M. Lippman, A.J. Dannenberg, et al. 2006. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin. Cancer Res. 12: 3661-3697.
13. Scott, E., W.P. Steward, A.J. Gescher & K. Brown. 2011. Resveratrol in human cancer chemoprevention - choosing the "right" dose. Mol. Nutr. Food Res. 56: 7-13.
14. Boocock, D.J., G.E. Faust, K.R. Patel, et al. 2007. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 16: 1246-1252.
15. Brown, V., K. Patel, M. Viskaduraki, et al. 2010. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Res. 70: 9003-9011.
16. Rotches Ribalta, M., C. Andres-Lacueva, R. Estruch, et al. 2012. Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine and grape extract tablets. Pharmacol. Res. 66: 375-382.
17. Bode, L.M., D. Bunzel, M. Huch, et al. 2013. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am. J. Clin. Nutr. 97: 295-309.
18. Patel, K.R., V.A. Brown, D.J.L. Jones, et al. 2010. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 70: 7392-7399.
19. Howells, L.M., D.P. Berry, P.J, Elliott, et al. 2011. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. 4: 1419-1425.
20. Williams, L.D., G.A. Burdock, J.A. Edwards, et al. 2009. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem. Toxicol. 47: 2170-2182.
21. Johnson, W.D., R.L. Morrissey, A.L. Usborne, et al. 2011. Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity. Food Chem. Tox. 49: 3319-3327.
22. Almeida, L., M. Vaz-da-Silva, A. Falcao, et al. 2009. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 53(Suppl 1): S7-S15.
23. la Porte, C., N. Voduc, G. Zhang, et al. 2010. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin. Pharmacokinet. 49: 449-454.
24. Chow, H.H., L.L. Garland, C.H. Hsu, et al. 2010. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev. Res. 3: 1168-1175.
25. Popat, R., T. Plesner, F. Davies, et al. 2013. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br. J. Haematol. 160: 714-717.
26. Butt, A.J., S.M. Firth & R.C. Baxter. 1999. The IGF axis and programmed cell death. Immunol. Cell Biol. 77: 256-262.
27. Ibrahim, Y.H. & D. Yee. 2004. Insulin-like growth factor-1 and cancer risk. Growth Horm. IGF Res. 14: 261-269.
28. Lopez, T. & D. Hanahan. 2002. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic isle tumorigenesis. Cancer Cell 1: 339-353.
29. Samani, A.A., E. Chevet, L. Fallavollita, et al. 2004. Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Res. 64: 3380-3385.
30. Sandhu, M.S., D.B. Dunger & E.L. Giovannucci. 2002. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J. Natl. Cancer Inst. 94: 972-980.
31. Renehan, A.G., M. Zwahlen, C. Minder, et al. 2004. Insulin-like growth factor (IGF)-1, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353.
32. Nguyen, A.V., M. Martinez, M.J. Stamos, et al. 2009. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag. Res. 1: 25-37.
33. Jun, H.T., J. Stevens & P. Kaplan-Lefko. 2008. Top NOTCH targets: notch signaling in cancer. Drug Develop. Res. 69: 319-328.
34. Grifantini, K. 2008. Understanding pathways of calorie restriction: a way to prevent cancer? J. Natl. Cancer Inst. 100: 619-621.
35. Timmers, S., E. Konings, L. Bilet, et al. 2011. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 14: 612-622.
36. Yoshino, J., C. Conte, L. Fontana, et al. 2012. Resveratrol supplementation does not improve metabolic function in non-obese women with normal glucose tolerance. Cell Metab. 16: 658-664.
37. Brasnyo, P., G.A. Molnar, M. Mohas, et al. 2011. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 106: 383-389.
38. Ghanim, H., C.L. Sia, K. Korzeniewski, et al. 2011. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J. Clin. Endocrinol. Metab. 96: 1409-1414.
39. Calabrese, E.J., M.P. Mattson & V. Calabrese. 2010. Resveratrol commonly displays hormesis: occurrence and biomedical significance. Hum. Exp. Toxicol. 29: 980-1015.